Integrated Nanotherapeutics Inc.
1 known investors
Integrated Nanotherapeutics (INT) is a preclinical-stage biotech developing antigen-specific immune tolerance therapies using lipid nanoparticles to treat autoimmune diseases such as Type 1 Diabetes, Multiple Sclerosis, and allergy. Its lead program, INT-101, targets Type 1 Diabetes, and the company also offers an LNP-based drug delivery platform for small molecules and nucleic acids.
BiotechDeep TechHealthtech